Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ASP101G + ASP2802 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASP101G | ASP 101G|ASP-101G|MA-20|MA20 | Limited information is currently available on ASP101G (Jul 2024). | ||
ASP2802 | ASP-2802|ASP 2802 | Limited information is currently available on ASP2802, a putative chimeric antigen receptor (CAR) T-cell therapy (May 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06248086 | Phase I | ASP101G + ASP2802 | A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas | Recruiting | AUS | 0 |